Navigation Links
Spero Therapeutics Acquires Next Generation Antibacterial Candidates from Pro Bono Bio for Treatment of Multidrug-Resistant, Gram-Negative Infections
Date:1/31/2017

CAMBRIDGE, Mass., Jan. 31, 2017 /PRNewswire-USNewswire/ -- Spero Therapeutics, LLC, a biopharmaceutical company founded to develop novel therapies for the treatment of bacterial infections, today announced it has acquired a next generation set of antibacterial candidates from Pro Bono Bio Ltd (PBB) to bolster its pipeline addressing the increased prevalence of multi-drug resistant forms of Gram-negative bacteria.   The assets acquired have been developed by Cantab Anti Infectives Ltd, a PBB group company.

"The acquisition of these antibacterial candidates from PBB demonstrates our commitment to finding new approaches to treat multi-drug resistant bacterial infections that continue to pose a serious threat to society. We are continuing to build our pipeline of differentiated anti-infectives and are excited to have gained access to this next-generation set of candidates for further study," said Ankit Mahadevia, M.D., Chief Executive Officer of Spero.

Michael Earl, Chief Operating Officer of PBB, added "We believe that the antibacterial candidates discovered by Cantab have the potential to provide novel, safer alternatives to treat serious Gram-negative infections. We are pleased to transition the program to the highly experienced team at Spero Therapeutics who possesses the specific know how needed to bring the program through pre-clinical and clinical stages of development in this therapy area."

Spero will continue to work collaboratively with Cantab to develop the acquired antibacterial compounds for treatment of multi-drug resistant strains of serious Gram-negative pathogens such as Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii. Under the terms of the agreement, Spero will receive all intellectual property associated with Cantab's program in exchange for undisclosed upfront and milestone payments, as well as royalties upon commercialization of any therapeutic candidates. 

The Cantab program is currently substantially funded by the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, through contract HHSN272201500014C, which is being used to evaluate the potential of these candidate compounds against certain Gram-negative Category A and B pathogens NIAID has identified as possible diseases of public health concern.  

About Spero

Spero Therapeutics is a global multi-asset clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts dedicated to developing a novel and highly differentiated pipeline of antibacterials focused on unmet needs of patients with drug resistant bacterial infections.  Spero Therapeutics is advancing two lead programs in parallel, SPR741 and SPR994.  SPR741, also called Potentiator, is a platform approach to combination therapy to treat serious and life-threatening multi-drug resistant gram negative infections, such as Enterobacteriaceae and Acinetobacter baumanii, including carbapenem resistant strains.  SPR741 increases the spectrum and potency of more than two dozen classes of gram positive antibiotics to include activity against multidrug resistant gram negative infections when used in combination.  SPR994 is a novel oral agent that has demonstrated potent invitro activity against a wide variety of gram-negative bacteria, including extended spectrum beta lactamases (ESBLs), and gram-positive bacteria.  Spero Therapeutics also has a robust preclinical pipeline including SPR720, which is a preclinical oral asset for nontuberculous mycobacteria (NTM) lung disease, a rare and often chronic fatal infection.  In addition, Spero Therapeutics has a variety of other discovery antimicrobials focused on drug-resistant infections. 

For more information, please visit https://sperotherapeutics.com.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/spero-therapeutics-acquires-next-generation-antibacterial-candidates-from-pro-bono-bio-for-treatment-of-multidrug-resistant-gram-negative-infections-300398954.html


'/>"/>
SOURCE Spero Therapeutics
Copyright©2017 PR Newswire.
All rights reserved


Related biology news :

1. Drug development venture links translational research, business to launch new therapeutics
2. Trovagene Announces Abstracts to be Presented at Molecular Targets and Cancer Therapeutics Conference
3. Arcturus Therapeutics Raises $5 Million in Series A Funding to Maintain its Momentum in Nominating Lead Clinical Candidate in 2014
4. Natura Therapeutics product shown to improve decision making skills in older adults
5. Emerging class of therapeutics represents a coming wave for developers and manufacturers
6. FASEB announces 2014 SRC: Translational Neuroimmunology: From Mechanisms to Therapeutics
7. Next-generation glaucoma therapeutics hold considerable promise
8. Nanomerics, UCL, H Lundbeck & Exeter University to research new brain therapeutics
9. Industry group release testing recommendations for oligonucleotide-based therapeutics
10. Splice-switching oligonucleotide therapeutics is new method for editing gene transcript
11. Human Longevity, Inc. and Celgene Cellular Therapeutics Sign License Agreement to Develop and Commercialize Placental Stem Cell Population, PSC-100 for Multiple Therapeutic Applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... , Feb. 27, 2017   Strategic Cyber ... announced it has led a $3.5 million investment in  ... platform. Strategic Cyber Ventures is DC based and is ... Hank Thomas . Ron Gula , also ... Ventures, also participated in this series A round of ...
(Date:2/24/2017)...  EyeLock LLC, a leader of iris-based identity ... biometric solution on the latest Qualcomm® Snapdragon™ 835 ... World Congress 2017 (February 27 – March ... 3, Stand 3E10. The Snapdragon ... platform—a combination of hardware, software and biometrics ...
(Date:2/21/2017)... PORTLAND, Ore. , Feb. 22, 2017 ... Family of Companies (Avamere Health Services, Infinity Rehab, Signature ... research study that will apply the power of IBM ... living and health centers. By analyzing data streaming from ... insights into physical and environmental conditions, and obtain deeper ...
Breaking Biology News(10 mins):
(Date:2/28/2017)... ... February 28, 2017 , ... RoviSys, a ... today that it has joined the Cisco® Digital Solutions Integrator Program. As a ... hardware and software that addresses Industrial IT and Business IT in manufacturing environments. ...
(Date:2/28/2017)... ... , ... Over 8,000 recognized rare diseases afflict an estimated 350 million people ... March 7, DrugDev will gather international experts to share challenges and provide insight and ... Overcoming the Challenges of Rare Disease Clinical Trials, Date: March 7, 2017, Time: 10:00-11:00 ...
(Date:2/28/2017)... ... February 28, 2017 , ... GigaGen Inc ... millions-diverse immune repertoires, today announced a strategic partnership with Trianni, Inc. , ... express human antibodies. The partnership will use GigaGen technology to discover immuno-oncology antibody ...
(Date:2/28/2017)... and PHILADELPHIA , Feb. 28, 2017 ... held biopharmaceutical company focusing on debilitating diseases including rare ... announced that the company joins with the National Organization ... advocacy and support around the world in commemorating Rare ... unique challenges and needs of the millions of patients ...
Breaking Biology Technology: